Agilent Seahorse Webinar Cell Analysis

Metabolic reprogramming as a therapeutic strategy for cutaneous squamous cell carcinoma 

Cutaneous squamous cell carcinomas (cuSCC) arising in different organ sites account for approximately 900,000 deaths worldwide annually, with 5% of these cases being locally advanced or metastatic. The 5-year survival of these patients is 25-35%, and effective chemotherapy or targeted therapy is lacking for advanced cuSCC*. Since aerobic glycolysis is an essential process that cancer cells use to fuel their uninterrupted growth, we hypothesized that cuSCC cell lines with high glycolytic activity would be responsive to therapeutic inhibition of glycolysis via an FDA-approved therapeutic for diabetes 1 & 2.  We utilized the Seahorse XF glycolytic rate assay to screen drug treated cuSCC cell lines, which identified cuSCC cell lines that were sensitive or resistant to this treatment.

In this webinar we will discuss:

  • How the glycolytic rate assay can be used for drug screening
  • Assessment of basal and compensatory glycolytic proton efflux rates following drug treatment
  • Using the glycolytic rate assay to screen potential mechanisms of drug action  


*Karia et al., (2012) JAAD. 68 (6): 957-966.

For Research Use Only.  Not for use in diagnostic procedures.

Thursday, May 3, 2018
8:00 PDT (Los Angeles)
11:00 EDT (New York)

16:00 GMT (London)

Available On Demand after May 3 
All registrants will be notified when available

Presented by:

Brian Murphy, Ph.D.
Research Scientist I, Laboratory of Elsa R. Flores, Ph.D.
Department of Molecular Oncology
Moffitt Cancer Center.

Learn more about Agilent Seahorse XF Technology